Observational analysis identified biomarkers affecting cumulative incidence in bladder cancer patients, suggesting critical gene interactions.
Introduction: Variable selection is increasingly becoming a key step in biomedical research, particularly in high-throughput genomic data analysis. One major focus is selecting relevant gene expression profiles associated with time-to-event outcomes, such as death. A significant challenge in this context is competing risks, where identifying a small subset of gene expression profiles related to the cumulative incidence function (CIF) is essential. Methods: Several methods have been proposed for directly modeling CIF, primarily by modeling the subdistribution hazard function for the event of interest. We proposed a regularized method for variable selection in the additive subdistribution hazards model by integrating five penalized likelihood approaches—Least Absolute Shrinkage and Selection Operator (LASSO), Adaptive LASSO (ALASSO), Elastic Net (ENET), Adaptive Elastic Net (AENET), and Smoothly Clipped Absolute Deviation (SCAD)—with the pseudoscore method. We conducted Monte Carlo simulations to evaluate the performance of our proposed method. Furthermore, the method was applied to a publicly available dataset of 301 patients diagnosed with non-muscle-invasive bladder carcinoma from five countries between 1987 and 2000. Results: Our proposed method was evaluated through simulation studies and applied to genomic data, focusing on progression-free survival as the endpoint and identifying the genes associated with the CIF of bladder cancer in the presence of competing events. Five genes, namely DCTD, IGF1R, NCF2, PLEK, and CDC20, were consistently identified across different penalties. Notably, the overexpression of DCTD and IGF1R was associated with a decreased cumulative incidence of bladder cancer progression or death. In contrast, the overexpression of NCF2, PLEK, and CDC20 correlated with an increased cumulative incidence of these events. Conclusion: According to the findings of the simulation studies, all penalties yielded comparable results in terms of sensitivity and specificity. However, the AENET and ALASSO ppenalties demonstrated superior estimation accuracy.
No takes yet. Share an insight, caveat, or question.
Tapak et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: